Literature DB >> 27702658

Inhibition of lysozyme fibrillation by human serum albumin nanoparticles: Possible mechanism.

Negar Mirzazadeh Dizaji1, Hossein Mohammad-Beigi2, Farhang Aliakbari3, Amir Tayaranian Marvian4, Seyed Abbas Shojaosadati5, Dina Morshedi6.   

Abstract

Amyloid fibrillation is a prevalent phenomenon in different proteins and peptides, which results in a variety of disorders. Over the last decade, implementation of nanoparticles (NPs), with or without drugs, is considered as a promising approach to protect against the aggregation process of amyloid proteins. In this study, we investigated the effect of human serum albumin NPs (HSA NPs) on the fibrillation of Hen Egg White Lysozyme (HEWL). The results showed that HSA NPs decrease the fibrillation of HEWL in a size dependent manner. Surprisingly, despite their inhibitory effects on the formation of long fibrils, our studies revealed that the NPs do not preserve the stability of the protein's structure in denaturing conditions. In fact, different structural analysis methods revealed that in the presence of the NPs, the protein's tendency to expose hydrophobic patches increased. Therefore, it seems that HSA NPs are responsible for decrease in HEWL fibrillation by reducing its concentration and blocking hot spot regions for self-assembly via moderate interaction. Collectively, our results shed light on the impact of HSA NPs on HEWL fibrillation and open new challenges on the implications of these NPs for drug delivery purposes or direct use as therapeutic agents.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amyloid fibrillation; Human serum albumin nanoparticles; Lysozyme

Mesh:

Substances:

Year:  2016        PMID: 27702658     DOI: 10.1016/j.ijbiomac.2016.09.108

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  1 in total

1.  Gold nanocolloid-protein interactions and their impact on β-sheet amyloid fibril formation.

Authors:  Heloise R Barros; Maria Kokkinopoulou; Izabel C Riegel-Vidotti; Katharina Landfester; Héloïse Thérien-Aubin
Journal:  RSC Adv       Date:  2018-01-03       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.